Matches in Wikidata for { <http://www.wikidata.org/entity/Q91438805> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- Q91438805 description "artículu científicu espublizáu en marzu de 2019" @default.
- Q91438805 description "im März 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q91438805 description "scientific article published on 05 March 2019" @default.
- Q91438805 description "wetenschappelijk artikel" @default.
- Q91438805 description "наукова стаття, опублікована 5 березня 2019" @default.
- Q91438805 name "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational" @default.
- Q91438805 name "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational" @default.
- Q91438805 type Item @default.
- Q91438805 label "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational" @default.
- Q91438805 label "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational" @default.
- Q91438805 prefLabel "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational" @default.
- Q91438805 prefLabel "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational" @default.
- Q91438805 P1433 Q91438805-7F69DD89-5651-4F09-9F80-69C135DE06F5 @default.
- Q91438805 P1476 Q91438805-4EE0F590-F90E-4CED-855A-6D0DA82587D8 @default.
- Q91438805 P2093 Q91438805-2243C839-2BA5-48EF-BF43-675ECF67F1FF @default.
- Q91438805 P2093 Q91438805-26C71EF5-24E6-43AF-9447-297938AD6B75 @default.
- Q91438805 P2093 Q91438805-40051B22-7388-4C0B-BA54-9BA268007DAE @default.
- Q91438805 P2093 Q91438805-49512AE1-B2CD-453C-A2DA-336E1725017C @default.
- Q91438805 P2093 Q91438805-6D1AA2D2-C99E-48DE-8FE1-0E852DB3DB43 @default.
- Q91438805 P2093 Q91438805-75C23971-63C2-4ABD-8FF7-EBDEC2FDE651 @default.
- Q91438805 P2093 Q91438805-CC8848A9-69A8-4F9B-88C0-B2B45AFD6279 @default.
- Q91438805 P2093 Q91438805-E5D2E22D-D543-43CC-BDAF-FDE814D92F4C @default.
- Q91438805 P2093 Q91438805-F04F8840-B151-47FC-A541-9C33CDA18395 @default.
- Q91438805 P2093 Q91438805-F1DCBCFE-D9E0-456F-B7ED-E60FAD251270 @default.
- Q91438805 P2093 Q91438805-FEF14856-23C2-44B9-B64E-53B44A907915 @default.
- Q91438805 P304 Q91438805-7EB076D0-32AB-48B7-88A3-5371F9053151 @default.
- Q91438805 P31 Q91438805-C436EE22-8055-460C-8AF5-9F605BE2442E @default.
- Q91438805 P356 Q91438805-9BD7B414-8FD3-4252-9459-BCEC44CE5E3F @default.
- Q91438805 P433 Q91438805-484702AC-C854-4B92-8203-9D848A58310C @default.
- Q91438805 P478 Q91438805-6C6CC307-E70A-499C-8B04-382C44A3FCCB @default.
- Q91438805 P50 Q91438805-1FA1CE89-B12A-4BE1-BD9C-6CA945168128 @default.
- Q91438805 P50 Q91438805-59C0B77A-02C8-4434-A0A2-898175144B6B @default.
- Q91438805 P50 Q91438805-DA65682C-5AC6-4A42-BDFF-C934ECE53D67 @default.
- Q91438805 P577 Q91438805-1BFFE2E6-25DA-417B-AAA2-E6E0339EF7E4 @default.
- Q91438805 P698 Q91438805-0B634C42-FC70-4A7F-8C2B-3315F2DC6247 @default.
- Q91438805 P921 Q91438805-01C433E2-5C75-4FD8-A4A9-B2C9C80B8DAA @default.
- Q91438805 P921 Q91438805-147E9666-588A-424C-8FDD-EC390F15E4E1 @default.
- Q91438805 P921 Q91438805-57AD7F56-0DE4-4318-95A7-7714869FDDC5 @default.
- Q91438805 P921 Q91438805-58C24FB3-9D39-4E1D-BDB9-46E790E2FFA5 @default.
- Q91438805 P921 Q91438805-A19BCFFF-FB09-4CA5-B369-5DE40F883D73 @default.
- Q91438805 P921 Q91438805-C57A6714-2475-447F-AB29-4E36B0C35967 @default.
- Q91438805 P921 Q91438805-C93265A4-DE82-4910-8410-CDCE95F64D72 @default.
- Q91438805 P932 Q91438805-C9526B21-E112-4685-9850-1C745AA94A82 @default.
- Q91438805 P356 JVH.13080 @default.
- Q91438805 P698 30739368 @default.
- Q91438805 P1433 Q15749962 @default.
- Q91438805 P1476 "Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries" @default.
- Q91438805 P2093 "David Back" @default.
- Q91438805 P2093 "Dominique Larrey" @default.
- Q91438805 P2093 "Eric Crown" @default.
- Q91438805 P2093 "Fiona Marra" @default.
- Q91438805 P2093 "Manuela Curescu" @default.
- Q91438805 P2093 "Mariem Charafeddine" @default.
- Q91438805 P2093 "Mark Bondin" @default.
- Q91438805 P2093 "Patrick Dorr" @default.
- Q91438805 P2093 "Peter Buggisch" @default.
- Q91438805 P2093 "Stefan Bourgeois" @default.
- Q91438805 P2093 "Suzanne Norris" @default.
- Q91438805 P304 "685-696" @default.
- Q91438805 P31 Q13442814 @default.
- Q91438805 P356 "10.1111/JVH.13080" @default.
- Q91438805 P433 "6" @default.
- Q91438805 P478 "26" @default.
- Q91438805 P50 Q43266970 @default.
- Q91438805 P50 Q56980311 @default.
- Q91438805 P50 Q61087037 @default.
- Q91438805 P577 "2019-03-05T00:00:00Z" @default.
- Q91438805 P698 "30739368" @default.
- Q91438805 P921 Q1414874 @default.
- Q91438805 P921 Q16824572 @default.
- Q91438805 P921 Q19462214 @default.
- Q91438805 P921 Q19598175 @default.
- Q91438805 P921 Q421862 @default.
- Q91438805 P921 Q422618 @default.
- Q91438805 P921 Q708693 @default.
- Q91438805 P932 "6849558" @default.